Publicaciones en las que colabora con Rocío García Carbonero (7)

2021

  1. Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)

    Journal of Clinical Oncology, Vol. 39, Núm. 20, pp. 2304-2312

2020

  1. Epigenetic EGFR gene repression confers sensitivity to therapeutic BRAFV600E blockade in colon neuroendocrine carcinomas

    Clinical Cancer Research, Vol. 26, Núm. 4, pp. 902-909

  2. The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)

    Oncologist, Vol. 25, Núm. 9, pp. 745-e1265

2019

  1. Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)

    Scientific Reports

  2. Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

    Scientific Reports, Vol. 9, Núm. 1

  3. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)

    British Journal of Cancer, Vol. 121, Núm. 7, pp. 537-544

  4. Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study

    Oncologist, Vol. 24, Núm. 1, pp. 38-46